Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
86pct
51d open
vs 5,357 other S bills in the 117th — cohort avg 38d
Inventor Diversity for Economic Advancement Act of 2021 or the IDEA Act This bill requires the U.S. Patent and Trademark Office (USPTO) to request demographic information from the inventor on each patent application submitted to the USPTO. Inventors shall not be required to provide the requested information, which shall include gender, race, and military or veteran status. The USPTO shall (1) publish an annual public report about the collected data, including the collected data broken down by the types of technology covered by the patent applications; and (2) make the underlying data publicly available.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S1425-1426)
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2022 · fourth_quarter · Copyright/Patent/Trademark
I have discussed patent eligibility issues and potential amendments to 35 USC 101, including S.4734 (the Patent Eligibility Restoration Act of 2022). I have also discussed potential amendments to the inter partes review process (35 USC 311 et seq), including those proposed in previous Congresses, e.g., S.2082 and H.R.3666 (STRONGER Patents Act of 2019). I have also addressed some of the provisions relating to patent litigation contained in these two bills (such as the abrogation of the holding in eBay v. MercExchange). I have discussed discretionary denials of institution by the Patent Trial and Appeals Board (PTAB) and potential remedies for the potential Appointments Clause problem for the PTAB, which are addressed in S.2891 (Restoring the America Invents Act). I have also discussed general patent quality issues and the funding of the U.S. Patent and Trademark through fees, which do not relate directly (for now) to any particular bill. I have also discussed the mandatory recordation of patent assignments as addressed in S.2774 (Pride in Patent Ownership Act). Finally, I have discussed efforts to expand innovation and patenting to be more inclusive of persons with diverse backgrounds, including two bills that would authorize the Patent and Trademark Office to collect certain voluntarily-submitted demographic information: e.g., H.R.1723 and S.632 (the IDEA Act) and one that would take a variety of other actions to expand American innovation: S.2773 (Unleashing American Innovators Act of 2021). Additionally, I have advocated against H.R.5874 - the Restoring Americas Leadership in Innovation Act of 2021 and in favor of S.4417 - the Patent Trial and Appeal Board Reform Act of 2022.
Client expense: Not reported · Firm income: $99,000
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
2022 · fourth_quarter · Copyright/Patent/Trademark
H.R. 1723 - Inventor Diversity for Economic Advancement (IDEA) Act S. 632 - Inventor Diversity for Economic Advancement (IDEA) Act S. 2774 - Pride in Patent Ownership (PPO) Act S. 4417 - Patent Trial and Appeal Board (PTAB) Reform Act -- regarding policy issues affecting higher education institutions and their faculty and students
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Health Issues
H.R. 1195, Workplace Violence Prevention for Health Care and Social Service Worker Act OSHA Funding Draft resolution on treating racism as a public health crisis H.R. 9475, TEACH Act S. 3663, Kids Online Safety Act Draft educator mental health bill H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety Health Worker Shortage/Staffing Crisis Visas for international healthcare professionals Green New Deal for Health, Entirety Monitor the following: Public Law 117-169, Inflation Reduction Act, Prescription drug reform Public Law 117-159, Bipartisan Safer Communities Act H.R.5015, the Medicaid DSH Payment Adjustment Fairness Act, Hospital funding formula Abortion Access related issues H.R.7784, the Supporting Trauma Informed Education Practices Act H.R.7666, Restoring Hope for Mental Health and Well‐Being Act S.2110, Better Care Better Jobs Act Nurse Overtime and Patient Safety Act S.632, Health Force and Resilience Force Act, H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives Federal response to COVID-19 Pandemic H.R.3755, the Women's Health Protection Act, Entirety H.R.7116, 9-8-8 Implementation Act H.R.6833, the Affordable Insulin Now Act Mental health supports for educators S.3796/H.R.7045, Closing Health Coverage Gaps for Public Servants Act Dobbs v. Jackson, United States Supreme Court decision Public Law 117-168, Honoring our Promise to Address Comprehensive Toxics (PACT) Act, Entirety
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Copyright/Patent/Trademark
Patent Eligibility Restoration Act (S.4734) Restoring Americas Leadership in Innovation Act (H.R.5874) Unleashing American Innovators Act (S.2773/H.R.8697) Inventor Diversity for Economic Advancement Act (S.632/H.R.1723) Patent Examination and Quality Improvement Act (S.4704) Patent Trial and Appeal Board Reform Act (S.4417) Pride in Patent Ownership Act (S.2774)
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · fourth_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Compulsory Licensing ---H.R.2148/S.909: Prescription Drug Price Relief Act ---H.R.4811: Medicare Negotiation and Competitive Licensing Act Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights ---TRIPS Waiver Data Privacy Issues ---H.R.8152: American Data Privacy and Protection Act ---S.2499: Setting an American Framework to Ensure Data Access, Transparency, and Accountability (SAFE DATA) Act Diversity in Patenting ---H.R.1723/S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications ---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---S.2773: Unleashing American Innovators Act of 2021 ---S.2774: Pride in Patent Ownership Act ---S.2891: Restoring the America Invents Act ---S.4430: Interagency Patent Coordination and Improvement Act of 2022 ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---TRIPS Waiver Inter Partes Review ---H.R.5874: Restoring America's Leadership in Innovation Act ---S.2774: Pride in Patent Ownership Act ---S.2891: Restoring the America Invents Act ---Implementation of the America Invents Act of 2011 ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) Patent Reform ---S.4417: Patent Trial and Appeal Board Reform Act of 2022 ---S.4430: Interagency Patent Coordination and Improvement Act of 2022 ---Patent Litigation Reform Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility ---Section 101 Modernization Patenting of Humanitarian Technologies ---H.R.5796: Patents for Humanity Act of 2021 United States-Mexico-Canada Agreement (USMCA) ---Mexico Draft Decree Banning Genetically Modified Corn
Client expense: $3,740,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
2022 · fourth_quarter · Copyright/Patent/Trademark
S. 4704, the Patent Examination and Quality Improvement Act of 2022 S. 4417, the PTAB Reform Act S. 4430, the Interagency Patent Coordination and Improvement Act of 2022. S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
2022 · third_quarter · Copyright/Patent/Trademark
H.R. 5874 - Restoring Americas Leadership in Innovation Act (RALIA) H.R. 8697 - Unleashing American Innovators Act H.R. 1723 - Inventor Diversity for Economic Advancement (IDEA) Act S. 2774 - Pride in Patent Ownership Act S.4734 - Patent Eligibility Restoration Act of 2022 S.2773 - Unleashing American Innovators Act S.632 - Inventor Diversity for Economic Advancement (IDEA) Act S.4704 - Patent Examination and Quality Improvement Act S.4417 - Patent Trial and Appeal Board (PTAB) Reform Act -- regarding policy issues affecting higher education institutions and their faculty and students
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Copyright/Patent/Trademark
Patent Act 101-03 35 USC Section 101 IDEA Act S.632/H.R. 1723 Unleashing American Innovators Act S.2773/H.R.8697 SBIR/STTR Programs
Client expense: $1,970,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Patent & Trademark Office (PTO)
2022 · third_quarter · Health Issues
Public Law 117-169, Inflation Reduction Act, Prescription drug reform Public Law 117-159, Bipartisan Safer Communities Act Monitor the following: H.R.5015, the Medicaid DSH Payment Adjustment Fairness Act, Hospital funding formula Abortion Access related issues H.R.7784, the Supporting Trauma Informed Education Practices Act H.R.7666, Restoring Hope for Mental Health and Well‐Being Act S.2110, Better Care Better Jobs Act Nurse Overtime and Patient Safety Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety S.632, Health Force and Resilience Force Act, H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives Federal response to COVID-19 Pandemic H.R.3755, the Women's Health Protection Act, Entirety Health Worker Shortage/Staffing Crisis H.R.7116, 9-8-8 Implementation Act H.R.6833, the Affordable Insulin Now Act Mental health supports for educators S.3796/H.R.7045, Closing Health Coverage Gaps for Public Servants Act S.4182, Workplace Violence Prevention for Health Care and Social Service Worker Act Dobbs v. Jackson, United States Supreme Court decision Visas for international healthcare professionals Public Law 117-168, Honoring our Promise to Address Comprehensive Toxics (PACT) Act, Entirety
2022 · third_quarter · Copyright/Patent/Trademark
Patent Eligibility Restoration Act (S.4734) Restoring Americas Leadership in Innovation Act (H.R.5874) Unleashing American Innovators Act (S.2773/H.R.8697) Inventor Diversity for Economic Advancement Act (S.632/H.R.1723) Patent Examination and Quality Improvement Act (S.4704) Patent Trial and Appeal Board Reform Act (S.4417) Pride in Patent Ownership Act (S.2774)
Client expense: $80,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · third_quarter · Copyright/Patent/Trademark
Patent Examination and Quality Improvement Act of 2022 S. 4417, the PTAB Reform Act S. 4430, the Interagency Patent Coordination and Improvement Act of 2022. S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
2022 · second_quarter · Copyright/Patent/Trademark
S. ____ - Stronger Patents Act S. 632 - Inventor Diversity for Economic Advancement (IDEA) Act -- regarding policy issues affecting higher education institutions and their faculty and students
Client expense: $220,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · second_quarter · Health Issues
H.Res.1141, Educator Mental Health Awareness Week Resolution Mental health supports for educators H.R.7828, the PRICED Act H.R. 4132, the Womens Health Protection Act Prescription drug reform, reconciliation H.R. 7784, the Supporting Trauma Informed Education Practices Act Medicare for All H.R.7666, Restoring Hope for Mental Health and Well‐Being Act S.3796/H.R.7045, Closing Health Coverage Gaps for Public Servants Act S.4182, Workplace Violence Prevention for Health Care and Social Service Worker Act Dobbs v. Jackson, United States Supreme Court decision Monitor the following: H.R.5015, the Medicaid DSH Payment Adjustment Fairness Act, Hospital funding formula Reconciliation bill Abortion Access related issues S.2110, Better Care Better Jobs Act Nurse Overtime and Patient Safety Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety S.632, Health Force and Resilience Force Act, H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives Federal response to COVID-19 Pandemic H.R.3755, the Women's Health Protection Act, Entirety Health Worker Shortage/Staffing Crisis H.R.7116, 9-8-8 Implementation Act H.R.6833, the Affordable Insulin Now Act
2022 · second_quarter · Copyright/Patent/Trademark
S. 4417, the PTAB Reform Act S. 4430, the Interagency Patent Coordination and Improvement Act of 2022. S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
2022 · first_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights ---TRIPS Waiver ---Coronavirus Supplemental Appropriations Data Privacy Issues ---US-EU Privacy Shield Diversity in Patenting ---H.R.1723/S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873/S.1435: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications ---H.R.2884/S.1435: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act ---H.R.4811: Medicare Negotiation and Competitive Licensing Act ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---TRIPS Waiver Inter Partes Review ---S.2774: Pride in Patent Ownership Act ---S.2891: Restoring the America Invents Act ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) ---Implementation of America Invents Act of 2011 Patent Reform ---S.1260: United States Innovation and Competition Act of 2021 ------Ownership and Assignments of Patents ---Patent Litigation Reform Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility ---Section 101 Modernization
Client expense: $3,170,000 · Firm income: Not reported
2022 · first_quarter · Copyright/Patent/Trademark
Legislative & Regulatory Issues Related to Intellectual Property, including Patents, Copyright, and Trademarks: Patent Eligible Subject Matter legislation; H.R. 1723, S. 632, Inventor Diversity for Economic Advancement Act (IDEA Act); S. 2774, Pride in Patent Ownership Act; H.R. 3429, SHOP SAFE Act provision within H.R. 4521, American COMPETES Act; S. 3880, SMART Copyright Act.
Client expense: $1,040,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2022 · first_quarter · Health Issues
S.3796/H.R.7045, Closing Health Coverage Gaps for Public Servants Act H.R.7116, 9-8-8 Implementation Act H.R.6833, the Affordable Insulin Now Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Worker Act Monitor the following: H.R.5015, the Medicaid DSH Payment Adjustment Fairness Act, Hospital funding formula H.R.5376, Build Back Better Act S.2110, Better Care Better Jobs Act Nurse Overtime and Patient Safety Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety S.632, Health Force and Resilience Force Act, H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives Federal response to COVID-19 Pandemic H.R.3755, the Women's Health Protection Act, Entirety Health Worker Shortage/Staffing Crisis
Client expense: $350,000 · Firm income: Not reported
2022 · first_quarter · Copyright/Patent/Trademark
S. 3880, the SMART Copyright Act of 2022 S. 3772, the Defending American Courts Act H.R. 6769, the Pro Codes Act H.R. 6570, the REPAIR Act H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act S, 3549, the Agricultural Right to Repair Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
2021 · fourth_quarter · Copyright/Patent/Trademark
I have discussed patent eligibility issues and potential amendments to 35 USC 101. Members of the House and Senate Judiciary Committees have publicly expressed interest in introducing a bill, but no bill has been introduced to date. I have also discussed potential amendments to the inter partes review process (35 USC 311 et seq), including those proposed in last Congress's S.2082 and H.R.3666 (STRONGER Patents Act of 2019). I have also addressed some of the provisions relating to patent litigation contained in these two bills (such as the abrogation of the holding in eBay v. MercExchange). I have discussed discretionary denials of institution by the Patent Trial and Appeals Board (PTAB) and potential remedies for the potential Appointments Clause problem for the PTAB, both of which are addressed in S.2891 (Restoring the America Invents Act). I have also discussed general patent quality issues and the funding of the U.S. Patent and Trademark through fees, which do not relate directly (for now) to any particular bill. I have also discussed the mandatory recordation of patent assignments as addressed in S.2774 (Pride in Patent Ownership Act). Finally, I have discussed efforts to expand innovation and patenting to be more inclusive of persons with diverse backgrounds, including two bills that would authorize the Patent and Trademark Office to collect certain voluntarily-submitted demographic information: H.R.1723 and S.632 (the IDEA Act) and one that would take a variety of other actions to expand American innovation: S.2773 (Unleashing American Innovators Act of 2021).
Client expense: Not reported · Firm income: $95,000
2021 · fourth_quarter · Health Issues
H.R.5015, the Medicaid DSH Payment Adjustment Fairness Act, Hospital funding formula Monitor the following: H.R.5376, Build Back Better Act S.2110, Better Care Better Jobs Act Nurse Overtime and Patient Safety Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety S.632, Health Force and Resilience Force Act, H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives Federal response to COVID-19 Pandemic
Client expense: $400,000 · Firm income: Not reported
2021 · fourth_quarter · Copyright/Patent/Trademark
Legislative & Regulatory Issues Related to Intellectual Property, including Patents, Copyright, and Trademarks: Patent Eligible Subject Matter legislation; draft Digital Copyright Act of 2021; Transitional Covered Business Method Patent Review Proceeding; H.R. 1723, S. 632, Inventor Diversity for Economic Advancement Act (IDEA Act); WTO TRIPS Waiver proposal; S. 2774, Pride in Patent Ownership Act.
Client expense: $1,060,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Science & Technology Policy (OSTP), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA), White House Office
2021 · fourth_quarter · Copyright/Patent/Trademark
H.R. 5902, the CLEAR Patents Act of 2021 H.R. 5874, Restoring Americas Leadership in Innovation Act of 2021 S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5184, the Advancing Americas Interests Act H.R. 5374, the SHOP SAFE Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 1159, To enhance the authority of U.S. Customs and Border Protection to share information S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: $10,000 · Firm income: Not reported
2021 · fourth_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---Domestic Manufacturing Requirement ---March-In Rights Compulsory Licensing ---H.R.2148/S.909: Prescription Drug Price Relief Act ---H.R.4811: Medicare Negotiation and Competitive Licensing Act Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights ---TRIPS Waiver Diversity in Patenting ---H.R.1723/S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873/S.1435: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2883/S.1485: Stop Stalling Access to Affordable Medications ---H.R.2884/S.1435: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---H.R.2891/S.1428: Preserve Access to Affordable Generics and Biosimilars Act ---H.R.4811: Medicare Negotiation and Competitive Licensing Act ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---China ---General Patent Reform ---TRIPS Waiver Inter Partes Review ---S.2774: Pride in Patent Ownership Act ---S.2891: Restoring the America Invents Act ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) Patent Reform ---S.1260: United States Innovation and Competition Act of 2021 ------Ownership and Assignments of Patents Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility ---Section 101 Modernization Patenting of Humanitarian Technologies ---H.R.5796: Patents for Humanity Act of 2021 US-China Trade Agreement ---IP Provisions
2021 · third_quarter · Copyright/Patent/Trademark
I have discussed patent eligibility issues and potential amendments to 35 USC 101. Members of the House and Senate Judiciary Committees have publicly expressed interest in introducing a bill, but no bill has been introduced to date. I have also discussed potential amendments to the inter partes review process (35 USC 311 et seq), including those proposed in last Congress's S.2082 and H.R.3666 (STRONGER Patents Act of 2019). I have also addressed some of the provisions relating to patent litigation contained in these two bills (such as the abrogation of the holding in eBay v. MercExchange). I have discussed discretionary denials of institution by the Patent Trial and Appeals Board (PTAB) and potential remedies for the potential Appointments Clause problem for the PTAB, both of which are addressed in S.2891 (Restoring the America Invents Act). I have also discussed general patent quality issues and the funding of the U.S. Patent and Trademark through fees, which do not relate directly (for now) to any particular bill. I have also discussed the mandatory recordation of patent assignments as addressed in S.2774 (Pride in Patent Ownership Act). Finally, I have discussed efforts to expand innovation and patenting to be more inclusive of persons with diverse backgrounds, including two bills that would authorize the Patent and Trademark Office to collect certain voluntarily-submitted demographic information: H.R.1723 and S.632 (the IDEA Act) and one that would take a variety of other actions to expand American innovation: S.2773 (Unleashing American Innovators Act of 2021).
Client expense: Not reported · Firm income: $96,750
2021 · third_quarter · Copyright/Patent/Trademark
Legislative & Regulatory Issues Related to Intellectual Property, including Patents, Copyright, and Trademarks: Patent Eligible Subject Matter Legislation; draft Digital Copyright Act of 2021; Transitional Covered Business Method Patent Review Proceeding; H.R. 1723, and S. 632, Inventor Diversity for Economic Advancement Act (IDEA Act); WTO TRIPS Waiver proposal; S. 2774, Pride in Patent Ownership Act.
Client expense: $1,250,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), Education, Dept of, Energy, Dept of, Federal Bureau of Investigation (FBI), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Institute of Standards & Technology (NIST), Natl Security Council (NSC), Natl Telecommunications & Information Administration (NTIA), Office of Management & Budget (OMB), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · third_quarter · Health Issues
Monitor the following: S.2110, Better Care Better Jobs Act Nurse Overtime and Patient Safety Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety S.632, Health Force and Resilience Force Act, H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Executive actions on An America-First Healthcare Plan Executive Order on Lowering Drug Prices by Putting America First Executive Order on Improving Rural Health and Telehealth Access Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order on Access to Affordable Life-saving Medications Lower Drug Costs Now Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives
Client expense: $450,000 · Firm income: Not reported
2021 · third_quarter · Health Issues
21st Century Cures Act 2.0 ---House Energy and Commerce Discussion Draft ---RFI from House Energy and Commerce Committee Biodefense Research, Development and Procurement Issues (Non-Funding) ---Executive Order on Modernizing Influenza Vaccines --- Implementation of 21st Century Cures Act of 2016 --- Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation (PAHPAI) Act of 2019 --- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 --- Implementation of the Families First Coronavirus Response Act of 2020 ---White House National Biodefense Strategy Biosimilars ---BSUFA Negotiations ---Reimbursement --- H.R. 2891/S.1428, the Preserve Access to Affordable Generics and Biosimilars Act; Coronavirus (COVID-19) Pandemic ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.869/S.289: Research Investment to Spark the Economy (RISE) Act of 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---COVID-19 Lessons Learned ---COVID-19 Pricing-Related Provisions ---COVID-19 Vaccine Distribution ---Defense Production Act (DPA) ---Drug Supply Chain Management ---Healthcare Disparities ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 --- Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 --- Implementation of the Families First Coronavirus Response Act of 2020, ---Medicare Reimbursement Policies ---Monoclonal Antibody Coverage and Utilization ---Patient Cost-Sharing and Smoothing ---PREP Act COVID-19 Declaration Coverage for Private Sector Procurement ---R&D Funding for Medical Countermeasures ---Senate HELP Pandemic Preparedness White Paper ---Supply Chain Issues ---TRIPS IP Waiver ---Temporarily Refundable R&D Credit ---NOL Monetization Diagnostics and Personalized Medicine Regulation and Oversight --- VALID Act (Discussion Draft) Diversity & Inclusion ---Clinical Trial Diversity ---ENACT Act ---DEPICT Act ---DIVERSE Act Drug Evaluation and Review ---COVID-19 Lessons Learned ---Compassionate Use/Expanded Access ---Expedited Pathways ---FDA Hiring Flexibility ---FDA Management and Financial Accountability ---Patient-Focused Drug Development ---Implementation of the Prescription Drug User Fee Act (PDUFA) VI ---Innovation Incentives ---Prescription Drug User Fee Act (PDUFA) VII Priorities ---Priority Review Voucher Programs ---Promising Pathway Act (Discussion Draft) ---Regulatory Reform & Modernization ---Use of Real-World Evidence ---Advisory Committee Enhancements Drug Importation ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) Drug Manufacturing, Quality & Distribution ---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft) ---Inspections Drug Patenting ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 --- H.R. 2891 Preserve Access to Affordable Generics and Biosimilars ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Lower Health Care Costs for Patients Act (Discussion Draft) ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---Restrictions on Intellectual Property Rights Drug Pricing ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---H.R. 2883/S.1425: the Stop Stalling Access to Affordable Medications; ---H.R. 2891/S.1428: the Preserve Access to Affordable Generics and Biosimilars Act; ---H.R. 2873: the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; ---H.R. 2884: the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act; ---H.R. 3684 - Infrastructure Investment and Jobs Act? ---S.1435, Affordable Prescriptions for Patients Act of 2021 ---S.632/H.R. 1732, IDEA Act ---HR 5125 Strengthening Innovation in Medicare/Medicaid ---EO 14036 on Competition in American Economy Under importation ---CMMI Authority ---COVID-19 Pricing-Related Provisions ---Drug Pricing Provisions ---Medicare Drug Price Negotiation Act (Discussion Draft) ---Prescription Drug Pricing Reduction Act (Discussion Draft) ---Reference Pricing in Drug Reimbursement ---Senate Finance Committee Drug Pricing Principles ---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft) Funding for Antimicrobial Resistance Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R. 4127, the DISARM Act ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R. 5376: Build Back Better Act ---Funding for Strategic National Stockpile ---Health Defense Operations Funding Designation ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Funding for FDA ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Implementation of the Prescription Drug User Fee Act (PDUFA) VI ---Prescription Drug User Fee Act (PDUFA) VII Priorities Funding for Health Resources and Services Administration (HRSA) ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 Funding for National Institutes of Health ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 ---Advanced Research Projects Agency for Health (ARPA-H) Funding for the Centers for Disease Control and Prevention Vaccine Programs ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.1319: American Rescue Plan Act of 2021 ---Funding for 2020-2021 Influenza Season Preparedness and Response ---Funding for Routine Immunization Infrastructure during Pandemic ---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020 Medicaid ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021 ---Pricing and Rebates ---Senate Finance Committee Drug Pricing Principles ---Value-Based Purchasing (VBP) Rule ---Alternative Payment Arrangements for Gene Therapies ---Drug Benefit Design Opioid Crisis ---FDA Reforms Orphan Drug Issues ---H.R. 5376: Build Back Better Act ---Tax Credit Reimbursement and Coverage of Innovative Products ---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---Administrative Rebate Rule ---CMMI Authority ---Drug Pricing Provisions ---Medicare Part B Physician-Administered Products ---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft) ---Patient Cost-Sharing and Smoothing ---Protected Classes ---Reference Pricing in Drug Reimbursement ---Senate Finance Committee Drug Pricing Principles ---Step Therapy ---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft) ---Value-Based Purchasing (VBP) Rule Vaccines and Infectious Diseases ---FY 2022 Appropriations ---H.R.133: Consolidated Appropriations Act for FY 2021 ---H.R.550: Immunization Infrastructure Modernization Act ---H.R.951: Maternal Vaccinations Act ---H.R.979: Vaccine Fairness Act ---H.R.1319: American Rescue Plan Act of 2021 ---H.R.1452: A bill to direct the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines, and for other purposes. ---H.R.1550: Promoting Resources to Expand Vaccination, Education, and New Treatments for (PREVENT) HPV Cancers Act of 2021 ---H.R.1978: Protecting Seniors through Immunizations Act ---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021 ---H.R.3013: COVID Vaccine Transportation Access Act ---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021 ---H.R.3742: Vaccine Information for Nursing Facility Operators (INFO) Act ---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act ---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes. ---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021 ---S.581: Helping Adults Protect Immunity (HAPI) Act of 2021 ---Adult Immunization ---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 ---MCM Manufacturing & Capacity ---MCM R&D Incentives ---Vaccine Injury Compensation Program ---Vaccine and Antimicrobial Resistance Product Development and Incentives Vaccine Injury Compensation Program ---FY 2022 Appropriations ---H.R.3656: Vaccine Access Improvement Act of 2021
2021 · third_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 --- H.R. 2891 Preserve Access to Affordable Generics and Biosimilars ---General Bayh-Dole Act/Tech Transfer ---Bayh-Dole Act ---March-In Rights ---NIST Proposed Rulemaking on Bayh-Dole Compulsory Licensing --- H.R.4811 - Medicare Negotiation and Competitive Licensing Act of 2021 --- Medicare Negotiation and Competitive Licensing Act (Discussion Draft) --- Prescription Drug Price Relief Act (Discussion Draft) --- We Protect American Investment in Drugs Act (Discussion Draft) Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights ---TRIPS Waiver Diversity in Patenting ---35 USC Section 101 on Patent Eligibility ---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---China ---TRIPS Waiver Inter Partes Review --- S.2891 Restoring the America Invents Act --- S.2774 Pride in Patent Ownership Act ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) Patent Reform ---S.1260: United States Innovation and Competition Act of 2021 ------Ownership and Assignments of Patents --- S.2774 Pride in Patent Ownership Act ---Patent Litigation Reforms Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility ---Section 101 Modernization United States-Mexico-Canada Agreement (USMCA) ---Implementation of USMCA US-China Trade Agreement ---IP Provisions
2021 · third_quarter · Copyright/Patent/Trademark
S. 2774, Pride in Patent Ownership S. 2773, Unleashing American Innovators Act S. 2891, the Restoring the America Invents Act H.R. 5374, the SHOP SAFE Act H.R. 4006 the Fair Repair Act H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products H.R. 3429, the SHOP SAFE Act S. 1843, the SHOP SAFE Act S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act S. 936, the INFORM Consumers Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to draft legislation on the Digital Millennium Copyright Act (DMCA) Issues related to the WTO TRIPs Waiver Request H.R. 4505, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2022
Client expense: $10,000 · Firm income: Not reported
2021 · second_quarter · Computer Industry
S.632, H.R. 1723 IDEA ACT; H.R.192 TROL ACT; STRONGER PATENTS ACT (Not yet re-introduced for 117th Congress) - Issues related to patent reform. SHOP SAFE Act S.1843 H.R. 3429; CASE ACT H.R. 285 - Issues related to copyright and trademarks. US Innovation and Competition ACT S.1260 - Issues related to US Standards system. General issues related to patent reform, copyright, and US Standards system
Client expense: $1,060,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense Advanced Research Projects Agency (DARPA), Defense, Dept of (DOD), Executive Office of the President (EOP), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Navy, Dept of, SENATE, Treasury, Dept of, U.S. Marines, U.S. Trade Representative (USTR)
2021 · second_quarter · Copyright/Patent/Trademark
Legislative & Regulatory Issues Related to Intellectual Property, including Patents, Copyright, and Trademarks: Patent Eligible Subject Matter Legislation; draft Digital Copyright Act of 2021; Transitional Covered Business Method Patent Review Proceeding; H.R. 1723, and S. 632, Inventor Diversity for Economic Advancement Act (IDEA Act); WTO TRIPS Waiver proposal.
Client expense: $980,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Education, Dept of, Energy, Dept of, HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Internal Revenue Service (IRS), Intl Trade Administration (ITA), Labor, Dept of (DOL), Natl Economic Council (NEC), Natl Science Foundation (NSF), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office
2021 · second_quarter · Copyright/Patent/Trademark
I have discussed patent eligibility issues and potential amendments to 35 USC 101. Members of the House and Senate Judiciary Committees have publicly expressed interest in introducing a bill, but no bill has been introduced to date. I have also discussed potential amendments to the inter partes review process (35 USC 311 et seq), including those proposed in last Congress's S.2082 and H.R.3666 (STRONGER Patents Act of 2019). I have also addressed some of the provisions relating to patent litigation contained in these two bills (such as the abrogation of the holding in eBay v. MercExchange). I have discussed discretionary denials of institution by the Patent Trial and Appeals Board (PTAB), potential remedies for the potential Appointments Clause problem for the PTAB, and general patent quality issues, which do not relate directly (for now) to any particular bill. Finally, I have discussed efforts to expand innovation and patenting to be more inclusive of persons with diverse backgrounds, including two bills that would authorize the Patent and Trademark Office to collect certain voluntarily-submitted demographic information: H.R.1723 and S.632 (the IDEA Act).
Client expense: Not reported · Firm income: $93,750
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
2021 · second_quarter · Health Issues
CARE Act Nurse Overtime and Patient Safety Act H.Res.304, Black Maternal Health Week H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety Monitor the following: S.632, Health Force and Resilience Force Act, S.263, Worker Health Coverage Protection Act (COBRA support) H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers, lobb Hazard pay for healthcare workers, lobby Domestic Policy Council, Department of Health and Human Services S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety Executive actions on An America-First Healthcare Plan Executive Order on Lowering Drug Prices by Putting America First Executive Order on Improving Rural Health and Telehealth Access Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order on Access to Affordable Life-saving Medications Healthcare extenders: continued delay of cuts to payments supporting disproportionate share hospitals and an extension of funding for Community Health Centers Lower Drug Costs Now Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic Pandemic Responder Service Award Act, Entirety H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives
2021 · second_quarter · Copyright/Patent/Trademark
S. 1260, the United States Innovation and Competition Act of 2021 H.R. 3978, To make it unlawful to send a demand letter in bad faith for a patent relating to COVID-19 related products S. 2067, the SECRETS Act S. 1924, the Protecting IP Act of 2021 S. 1294, the Protecting American Intellectual Property Act of 2021 S. 1245, CCP Trade Secrets Act H.R. 1367/S. 483, the Workforce Mobility Act of 2021 H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to international patent harmonization Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to draft legislation on the Digital Millennium Copyright Act (DMCA) Issues related to the WTO TRIPs Waiver Request Issues related to the US Court of Appeals for the Federal Circuit Nomination
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
2021 · second_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 Bayh-Dole Act/Tech Transfer ---FY 2022 Appropriations ---Bayh-Dole Act ---March-In Rights ---NIST Proposed Rulemaking on Bayh-Dole Compulsory Licensing Coronavirus (COVID-19) Pandemic ---Restrictions on Intellectual Property Rights Diversity in Patenting ---35 USC Section 101 on Patent Eligibility ---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.19/S.2164: Lower Costs, More Cures Act of 2021 ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 ---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021 ---S.1435: Affordable Prescriptions for Patients Act of 2021 ---Lower Health Care Costs for Patients Act (Discussion Draft) ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---China ---General Patent Reform ---TRIPS Waiver Inter Partes Review ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) Patent Reform ---H.R.7259/S.2814: Patents for Humanity Program Improvement Act of 2020 ---S.1260: United States Innovation and Competition Act of 2021 ------Ownership and Assignments of Patents ---Patent Litigation Reforms Patenting of Biological Inventions ---35 USC Section 101 on Patent Eligibility ---DNA Patenting and Licensing ---Section 101 Modernization United States-Mexico-Canada Agreement (USMCA) ---Implementation of USMCA ------IP Provisions US-China Trade Agreement ---IP Provisions
Client expense: $3,500,000 · Firm income: Not reported
2021 · first_quarter · Copyright/Patent/Trademark
I have discussed patent eligibility issues and potential amendments to 35 USC 101. Members of the House and Senate Judiciary Committees have publicly expressed interest in introducing a bill, but no bill has been introduced to date. I have also discussed potential amendments to the inter partes review process (35 USC 311 et seq), including those proposed in last Congress's S.2082 and H.R.3666 (STRONGER Patents Act of 2019). I have also addressed some of the provisions relating to patent litigation contained in these two bills (such as the abrogation of the holding in eBay v. MercExchange). I have discussed discretionary denials of institution by the Patent Trial and Appeals Board (PTAB), potential remedies for the potential Appointments Clause problem for the PTAB, and general patent quality issues, which do not relate directly (for now) to any particular bill. Finally, I have discussed efforts to expand innovation and patenting to be more inclusive of persons with diverse backgrounds, including two bills that would authorize the Patent and Trademark Office to collect certain voluntarily-submitted demographic information: H.R.1723 and S.632 (the IDEA Act).
Client expense: Not reported · Firm income: $93,750
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
2021 · first_quarter · Health Issues
S.632, Health Force and Resilience Force Act, S.263, Worker Health Coverage Protection Act (COBRA support) H.R.959/S.346, Black Maternal Health Momnibus Act Student Loan Forgiveness for Frontline Health Workers, lobb Hazard pay for healthcare workers, lobby Domestic Policy Council, Department of Health and Human Services S.102, the Prescription Drug Price Relief Act S.99, the Medicare Drug Price Negotiation Act S.97, the Affordable and Safe Prescription Drug Importation Act H.R.1195, Workplace Violence Prevention for Health Care and Social Service Workers Act, Entirety Nurse Staffing Standards for Hospital Patient Safety and Quality Care Act, Entirety H.R.1391/S.482, Taxpayer Research and Coronavirus Knowledge Act, Entirety H.R.7296/S.4439, Make Medications Affordable by Preventing Pandemic Pricegouging Act, Entirety COVID-19 related issues and initiatives, generally Monitor the following: Executive actions on An America-First Healthcare Plan Executive Order on Lowering Drug Prices by Putting America First Executive Order on Improving Rural Health and Telehealth Access Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen Executive Order on Increasing Drug Importation to Lower Prices for American Patients Executive Order on Access to Affordable Life-saving Medications Healthcare extenders: continued delay of cuts to payments supporting disproportionate share hospitals and an extension of funding for Community Health Centers Lower Drug Costs Now Act, Entirety Affordability of pharmaceuticals, generally Treating gun violence as a public health epidemic related issues Nurse Overtime and Patient Safety Act, Entirety The National Nurse Act, Entirety Health Equity Issues during COVID Pandemic Pandemic Responder Service Award Act, Entirety H.R.728/S.187, Pandemic Emergency Manufacturing Act of 2021, Entirety Support Medicare/ACA enrollment H.R. 6637, Health Equity and Accountability Act, Entirety Delivery of healthcare services to students during COVID pandemic Telehealth issues H.R.1227/S.386, Medicare X Choice Act Rural Healthcare related issues and initiatives
2021 · first_quarter · Copyright/Patent/Trademark
Antitrust Legislation ---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021 Bayh-Dole Act/Tech Transfer ---FY 2022 Appropriations ---Bayh-Dole 40th Anniversary ---Follow Up Discussions about State Attorney General Letter ---March-In Rights ---NIST Proposed Rulemaking on Bayh-Dole Compulsory Licensing ---Prescription Drug Price Relief Act (Discussion Drafts) ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---We Protect American Investment in Drugs Act (Discussion Draft) Coronavirus (COVID-19) Pandemic ---Bringing Back American Jobs Through Intellectual Property Repatriation Act (Discussion Draft House) ---Restrictions on Intellectual Property Rights Diversity in Patenting ---Implementation of Study of Underrepresented Classes Chasing Engineering and Science Success (SUCCESS) Act of 2018 ---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021 Drug Patenting ---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021 ---Affordable Prescriptions for Patients Act (Discussion Draft) ---Lower Costs, More Cures Act (Discussion Draft) ---Medicare Negotiation and Competitive Licensing Act (Discussion Draft) ---Restrictions on Intellectual Property Rights Intellectual Property Enforcement ---China ---India ---TRIPS Waiver Inter Partes Review ---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft) United States-Mexico-Canada Agreement (USMCA) ---Implementation of USMCA US-China Trade Agreement ---IP Provisions
Client expense: $3,060,000 · Firm income: Not reported
2021 · first_quarter · Copyright/Patent/Trademark
H.R. 1723/S. 632, IDEA Act H.R. 653, Research Advancing to Market Production for Innovators Act H.R. 192, Targeting Rogue and Opaque Letters Act H.R. 597, the Pandemic Treatment Access and Affordability Act of 2021 H.R. 153, Protecting Consumer Access to Generic Drugs Act of 2021 H.R. 704/S. 169, the ARTS Act H.R. 824, the Stop Chinas IP Theft Act S. 39, Protecting American Innovation and Development Act of 2021 Issues related to USPTO operations Issues related to patent subject matter eligibility Issues related to Copyright Office Modernization Issues related to draft legislation on the Digital Millennium Copyright Act (DMCA) Issues related to the WTO TRIPs Waiver Request Issues related to general IP policy
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
| Republican |
| IA |
| Patrick J. Leahy | Democratic | VT |
| Richard Blumenthal | Democratic | CT |
| Richard J. Durbin | Democratic | IL |
| Thom Tillis | Republican | NC |
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $370,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $350,000 · Firm income: Not reported
Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Client expense: $10,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Client expense: Not reported · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
Government targets: Agriculture, Dept of (USDA), Education, Dept of, HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $3,370,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Government targets: Commerce, Dept of (DOC), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, White House Office
Government targets: Agriculture, Dept of (USDA), Education, Dept of, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE, White House Office
Client expense: $3,360,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR), White House Office
Client expense: $3,360,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), U.S. Trade Representative (USTR), White House Office
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Library of Congress (LOC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Client expense: $380,000 · Firm income: Not reported
Government targets: Education, Dept of, Federal Communications Commission (FCC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Natl Security Council (NSC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Consumer Financial Protection Bureau (CFPB), Education, Dept of, Executive Office of the President (EOP), Federal Communications Commission (FCC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institute of Standards & Technology (NIST), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office